Across TCGA pan-cancer cohorts, CAPZA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CAPZA2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CAPZA2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CAPZA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where CAPZA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.977	0.484	.008	13	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	3	view →
GBM	OS	Median	All	0.637	0.888	.007	3	view →
HNSC	OS	Median	III,IV	0.556	0.758	.029	2	view →
CCRCC	OS	Median	All	1.000	0.754	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CAPZA2 tumor-vs-normal RNA expression · all CAPZA2 data types